Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
Zacks.com on MSN
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
NEW YORK, May 02, 2025--(BUSINESS WIRE)--Cartesian Growth Corporation III (the "Company") announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, ...
Factorial Inc. (“Factorial”), a leader in solid-state battery technology, today announced that, upon the closing of the ...
Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results